AstraZeneca shares will get lift from heartburn litigation closure, says CitiProactive Investors • 11/01/22
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer ResearchPRNewsWire • 10/27/22
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast CancerBusiness Wire • 10/26/22
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancerBusiness Wire • 10/26/22
AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpointsMarket Watch • 10/26/22
AstraZeneca trial of Fasrena fails to meet one of two dual-primary endpointsProactive Investors • 10/25/22
AstraZeneca says Imjudo-Imfinzi combination approved in advanced liver cancer in USProactive Investors • 10/24/22
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGCBusiness Wire • 10/18/22
AstraZeneca set for strong third-quarter; brokers think the stock is worth £125Proactive Investors • 10/17/22